RxDoctor Payments Data

Thomas Pritchard, MD

Cardiovascular Disease · Greenwood, SCNPI 1477545119

Payments from drug & device makers

$10,595in general payments, 2019–2025

Across 536 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Abbott$799
  • Boehringer Ingelheim$719
  • Amgen$658
  • AstraZeneca$618
  • plus $5K from 38 others

What the payments were for

  • Speaking & faculty fees$1091%
  • Food & beverage$10,48699%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,595 in reported general payments places this provider in the 75th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$187,661
Medicare patients
882
Services billed
3,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban523$501,426
EntrestoSacubitril/Valsartan270$242,009
XareltoRivaroxaban51$53,546
JardianceEmpagliflozin49$40,158
Repatha SureclickEvolocumab14$14,941
Metoprolol Succinate884$12,023
Amiodarone Hcl134$5,657
Bumetanide137$3,636
Losartan Potassium167$1,842
Diltiazem 24hr Er (Cd)Diltiazem Hcl85$1,799
Carvedilol200$1,585
Atorvastatin Calcium123$1,463
Ranolazine ErRanolazine23$1,435
Flecainide Acetate35$1,287
Isosorbide Mononitrate ErIsosorbide Mononitrate67$1,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$335$501,426523 claims
NovartisEntresto$1,485$242,009270 claims
Johnson & JohnsonXarelto$307$53,54651 claims
Boehringer IngelheimJardiance$719$40,15849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Greenwood

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →